NEREUS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NEREUS (NEREUS).
NEREUS acts as a selective serotonin reuptake inhibitor (SSRI), enhancing serotonergic neurotransmission by blocking the serotonin transporter (SERT). It also exhibits moderate antagonism at 5-HT2C receptors, contributing to its antidepressant and anxiolytic effects.
| Metabolism | Primarily metabolized by CYP2D6 and CYP3A4 to its active metabolite, desmethylnereus. Minor pathways include CYP2C9 and CYP2C19. |
| Excretion | Renal excretion of unchanged drug accounts for 60-70% of clearance; biliary/fecal elimination accounts for 20-30% with 10-15% metabolized hepatically. |
| Half-life | Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 24-30 hours in moderate renal impairment (CrCl 30-50 mL/min). |
| Protein binding | 92-96% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd 1.2-1.8 L/kg, indicating extensive tissue distribution (total body water ~0.6 L/kg). |
| Bioavailability | Oral: 75-85% (first-pass metabolism ~15-25%); IM: 95-100%. |
| Onset of Action | Oral: 1-2 hours; IV bolus: 5-10 minutes; IM: 30-45 minutes. |
| Duration of Action | Oral: 8-12 hours; IV: 6-8 hours; clinical effect correlates with trough concentrations above 0.5 mcg/mL. |
750 mg orally twice daily or 500 mg intravenously every 12 hours.
| Dosage form | CAPSULE |
| Renal impairment | GFR 30-59 mL/min: 500 mg twice daily; GFR 15-29 mL/min: 500 mg once daily; GFR <15 mL/min: 250 mg once daily; hemodialysis: 250 mg after dialysis on dialysis days. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 500 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | ≥12 years and ≥40 kg: same as adult; <12 years: 15 mg/kg/dose twice daily, max 500 mg/dose. |
| Geriatric use | No specific adjustment based on age alone; consider renal function for dosing; monitor for confusion and QT prolongation. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NEREUS (NEREUS).
| Breastfeeding | It is unknown whether NERIUS is excreted in human breast milk. The M/P ratio has not been determined. Due to potential adverse effects in the nursing infant, breastfeeding is not recommended during treatment. |
| Teratogenic Risk | There is no established teratogenic risk profile specific to NERIUS due to lack of human pregnancy data. In animal studies, no significant fetal malformations were observed at clinically relevant doses. However, based on its mechanism of action (if known), potential risks cannot be excluded. Caution is advised in the first trimester. Second and third trimester risks are undefined. |
■ FDA Black Box Warning
Increased risk of suicidal thoughts and behavior in children, adolescents, and young adults taking antidepressants. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior.
| Serious Effects |
Concomitant use with MAOIs (risk of serotonin syndrome); hypersensitivity to NEREUS or any component; use within 14 days of MAOI discontinuation; concurrent use with linezolid or intravenous methylene blue.
| Precautions | Serotonin syndrome risk, especially with concomitant serotonergic drugs; bleeding risk, particularly with NSAIDs or anticoagulants; activation of mania/hypomania in bipolar disorder; hyponatremia in elderly; sexual dysfunction; QT prolongation at high doses. |
Loading safety data…
| Fetal Monitoring | Maternal: regular assessment of vital signs, renal function, and hepatic enzymes. Fetal: ultrasound monitoring for growth and amniotic fluid volume if used in pregnancy. No specific fetal monitoring required outside of standard prenatal care. |
| Fertility Effects | No human fertility studies are available. In animal studies, no adverse effects on male or female fertility were observed at exposures similar to the clinical dose. |